NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Surges on Positive Guidance from FDA for DCCR in Prader-Willi Syndrome

Soleno Therapeutics (NASDAQ: SLNO) shares are up 11% on news that the company has received the minutes from a scientific advice meeting from the U.S. Food and Drug Administration (FDA) regarding Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi syndrome (PWS). The company previously submitted data from a phase II study of DCCR in PWS patients, as well as data from other studies conducted with DCCR. The company agreed with the FDA’s suggestion that the duration of the study should be shorter and that DCCR safety information could be obtained in a long-term, safety extension study. Soleno said it plans to finalize the design of a phase III, randomized, double-blind placebo-controlled study that will treat approximately 100 patients. Subject to final agreement by the FDA, the study is anticipated to start at the end of 2017. “We remain committed to the development of DCCR, which, if approved, could provide the desperately needed treatment for this life-threatening condition. Based on the clinical data generated to date, we believe DCCR has the potential to be a safe and effective treatment for PWS patients, and look forward to initiating this Phase III trial before the end of 2017,” Soleno CEO Anish Bhatnagar, M.D. stated in the news release.

To view the full press release, visit:

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a phase III clinical development program at the end of 2017. Soleno, through its wholly owned subsidiary, Capnia, Inc., continues to market Capnia’s innovative medical devices, including the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns, and the NeoForce portfolio of neonatal pulmonary resuscitation solutions. It is expected that these products will be monetized and will not be a focus for the company in the long term. For more information, please visit

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s